Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073603 · ClinicalTrials.gov registry record · Phase 4
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 259
- Enrollment target
NCT03073603 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 259 participants.
The verdict
NCT03073603, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 259 participants
- Enrollment target
Study Summary
Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older. Thus, the need to continue MS medicines that reduce relapses and new MRI lesions may also decrease as people age, especially in those who have not had relapses or MRI scan changes for prolonged times. This study plans to learn more about the safety of stopping MS medication in this population, as compared to continuing on the medication.
Interventions
- DRUG Standard of Care
- DRUG Discontinuation of disease modifying therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03073603
The ClinicalTrials.gov registry entry for NCT03073603 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03073603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03073603 about?
NCT03073603 is a clinical study titled "Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)". Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older. Thus, the need to continue MS medicines that reduce relapses and new MRI lesions may also d...
What is the current status of trial NCT03073603?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 259 participants. The study started on 2017-04-20. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT03073603?
The interventions under investigation include: Standard of Care (DRUG), Discontinuation of disease modifying therapy (DRUG).
Who is sponsoring clinical trial NCT03073603?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.